Golden, Colorado-December 10th, 2020-Vitro Diagnostics, Inc., dba Vitro Biopharmaannounced the appointment by its Board of Directors of Jack Zamora, MD as its new Chief Executive Officer (“CEO”) and the retention of Dr. James Musick, the current CEO as Chief Science Officer (“CSO”). Dr. Zamora adds new dimensions to Vitro Biopharma’s senior management team.
Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.
Vitro Diagnostics, Inc.(OTCPK: VODG), dbaVitro entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. (“GIOSTAR”) a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug
Dr. Jim Musick, Ph.D., CEO said, “We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells®.
Golden, Colorado-July20th, 2020-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that it has engaged MaloneBailey L.L.P. (Certified Public Accounting Firmwww.malonebailey.com) as its new auditors that will be auditing the company’s consolidated balance sheets as of October 31, 2019 and October 31, 2020,